Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Pyxis Oncology, Inc. shareholders approved Election of Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger as Class II Directors at the 2026-06-15 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-15
Exact text from the filing
Proposal One: Election of Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger as Class II Directors Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger were elected to serve as Class II directors to hold office until the Company’s 2029 Annual Meeting of Stockholders and until the election and qualification of their successors. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Mr. Thomas Civik 27,341,415 1,981,857 17,978,763 Dr. Freda Lewis-Hall, M.D. 19,188,755 10,134,517 17,978,763 Mr. Michael A. Metzger 26,521,575 2,801,697 17,978,763
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Pyxis Oncology, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-15 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-15
Exact text from the filing
Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following vote: For Against Abstain Broker Non-Votes 46,203,257 1,076,997 21,781 —
View on SEC.gov